GGrantIndex
← Search

PRIMARY BILIARY CIRRHOSIS--UDCA-METHOTREXATE TREATMENT PROTOCOL

$293,069M01FY2002RRNIH

Emory University, Atlanta GA

Investigators

Linked publications & trials

Abstract

This is a clinical trial of UDCA and MTX in the treatment of patients with PBC. UDCA appears to protect against the cytotoxic effects of endogenous bile acids that accumulate as a result of bile duct destruction. BMT is being shown to improve liver tests, symptoms and liver histology in a small number of pre-cirrhotic patients with PBC. The mechanism of action is unknown but is felt to be related to anti-inflammatory immunosuppressive effects of MTX.

View original record on NIH RePORTER →